In this issue:
ROS1+ NSCLC and elevated risk of TEE
IMpower150 data on ABCP in key patient subgroups
Avelumab in advanced unresectable mesothelioma
Plasma-based genotyping for therapy choices in metastatic NSCLC
KEYNOTE-024: pembrolizumab continues to show OS benefit
Tumour/plasma genotyping and clinical outcomes with lorlatinib
Folate/B12 supplementation and pemetrexed
cRT in ES SCLC improves PFS and reduces thoracic failures
SBRT ± adjuvant chemotherapy in early-stage NSCLC
Current palliative management of MPM in the UK and Australia justified
Please login below to download this issue (PDF)